Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHTHOUSE: ATSN-201 Gene Therapy in X-linked Retinoschisis
NCT05878860Phase 3Recruiting
- Sponsor
- Atsena Therapeutics
- Start
- Aug 2023
- Primary completion
- Apr 2028
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of ATSN-201 in X-linked retinoschisis (XLRS) (9 cohorts), sponsored by Atsena Therapeutics. Primary endpoints: Dose-limiting toxicities and treatment-emergent adverse events at 52 weeks and Effect of ATSN-201 on visual function at 52 weeks. Started Aug 2023; status: recruiting.
02
Drugs
ATSN-201
03
Conditions
X-linked retinoschisis (XLRS)
Beyond the preview
Go deeper on NCT05878860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05878860.